These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32409308)

  • 1. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of
    Maresca KP; Chen J; Mathur D; Giddabasappa A; Root A; Narula J; King L; Schaer D; Golas J; Kobylarz K; Rosfjord E; Keliher E; Chen L; Ram S; Pickering EH; Hardwick JS; Rejto PA; Hussein A; Ilovich O; Staton K; Wilson I; McCarthy TJ
    Mol Imaging Biol; 2021 Dec; 23(6):941-951. PubMed ID: 34143379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
    Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
    J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Schwenck J; Sonanini D; Seyfried D; Ehrlichmann W; Kienzle G; Reischl G; Krezer P; Wilson I; Korn R; Gonzalez-Menendez I; Quintanilla-Martinez L; Seith F; Forschner A; Eigentler T; Zender L; Röcken M; Pichler BJ; Flatz L; Kneilling M; la Fougere C
    Theranostics; 2023; 13(8):2408-2423. PubMed ID: 37215571
    [No Abstract]   [Full Text] [Related]  

  • 5. First-in-Humans Imaging with
    Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
    J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
    Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
    Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-PET Monitoring of CD8
    Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
    Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
    Claus C; Ferrara C; Xu W; Sam J; Lang S; Uhlenbrock F; Albrecht R; Herter S; Schlenker R; Hüsser T; Diggelmann S; Challier J; Mössner E; Hosse RJ; Hofer T; Brünker P; Joseph C; Benz J; Ringler P; Stahlberg H; Lauer M; Perro M; Chen S; Küttel C; Bhavani Mohan PL; Nicolini V; Birk MC; Ongaro A; Prince C; Gianotti R; Dugan G; Whitlow CT; Solingapuram Sai KK; Caudell DL; Burgos-Rodriguez AG; Cline JM; Hettich M; Ceppi M; Giusti AM; Crameri F; Driessen W; Morcos PN; Freimoser-Grundschober A; Levitsky V; Amann M; Grau-Richards S; von Hirschheydt T; Tournaviti S; Mølhøj M; Fauti T; Heinzelmann-Schwarz V; Teichgräber V; Colombetti S; Bacac M; Zippelius A; Klein C; Umaña P
    Sci Transl Med; 2019 Jun; 11(496):. PubMed ID: 31189721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
    Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
    Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager
    Waaijer SJH; Warnders FJ; Stienen S; Friedrich M; Sternjak A; Cheung HK; van Scheltinga AGTT; Schröder CP; de Vries EGE; Lub-de Hooge MN
    Clin Cancer Res; 2018 Oct; 24(20):4988-4996. PubMed ID: 29980531
    [No Abstract]   [Full Text] [Related]  

  • 14.
    England CG; Jiang D; Ehlerding EB; Rekoske BT; Ellison PA; Hernandez R; Barnhart TE; McNeel DG; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):110-120. PubMed ID: 28821924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
    Tavaré R; Escuin-Ordinas H; Mok S; McCracken MN; Zettlitz KA; Salazar FB; Witte ON; Ribas A; Wu AM
    Cancer Res; 2016 Jan; 76(1):73-82. PubMed ID: 26573799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular imaging of T cell co-regulator factor B7-H3 with
    Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
    Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
    Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
    Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG
    Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.